Publications by authors named "A Kutlar"
Article Synopsis
- * In research using mice, SCD was found to enhance vasoconstriction (narrowing of blood vessels) through the alpha-1 adrenergic receptor, particularly by increasing the expression of the alpha-1a receptor in the aortic tissue of SCD mice compared to controls.
- * Treatment with ambrisentan, an ETA receptor blocker, improved blood vessel function in both mice and SCD patients, suggesting that targeting the ET-1 pathway could help improve vascular health in individuals with
Background: Crizanlizumab is a novel inhibitor of P-selectin, a key player in multicellular adhesion and inflammatory signaling, that leads to vaso-occlusion in sickle cell disease (SCD).
Objectives: The SOLACE-adults study evaluated the pharmacokinetics, pharmacodynamics (P-selectin inhibition), safety, and efficacy of crizanlizumab, with or without hydroxyurea/hydroxycarbamide, in patients with SCD.
Design: Phase II, single-arm, multicenter study.
Article Synopsis
- Sickle cell disease (SCD) has different types, with HbSS being the most common and HbSC being the second most common.
- A study showed that people with HbSC disease, which was thought to be milder, actually experience more severe health problems compared to those with sickle cell anemia (SCA).
- The findings suggest that HbSC disease needs more research and better treatments because it can cause serious complications.
Article Synopsis
- Post-transfusion survival of donor red blood cells (RBCs) is crucial for effective treatment in conditions like sickle cell disease (SCD) and can be measured using biotin labeling.
- An observational study tested the survival of biotin-labeled RBCs in pediatric SCD patients receiving chronic transfusions, revealing one donor unit with microcytosis and alpha-thalassemia.
- The findings indicated that RBCs from donors with alpha-thalassemia may have a shorter survival post-transfusion, suggesting a need for more research on how these traits affect overall transfusion effectiveness.
Crizanlizumab, a monoclonal antibody against P-selectin, has been shown to reduce vaso-occlusive crises (VOCs) compared to placebo in patients ≥ 16 years with sickle cell disease (SCD). However, there have been rare reports of patients experiencing severe pain and subsequent complications within 24 hours of crizanlizumab infusions. These events are defined as infusion-related reactions (IRRs).
View Article and Find Full Text PDF